miR505 suppresses prostate cancer progression by targeting NRCAM.
Oncol Rep
; 42(3): 991-1004, 2019 Sep.
Article
em En
| MEDLINE
| ID: mdl-31322225
ABSTRACT
Previous researchers have demonstrated that microRNA505 (miR505) is negatively correlated with progression in various malignancies. However, the detailed function and molecular mechanisms of miR505 have yet to be completely elucidated in prostate cancer (PCa). The present study initially identified the potential role of miR505 in PCa using in vitro experiments, and demonstrated that restoration of miR505 inhibited proliferation, invasion and migration, yet induced cell cycle arrest and promoted apoptosis in PCa cells. The present study also demonstrated that the expression of neuronglialrelated cell adhesion molecule (NRCAM) was markedly upregulated in PCa cells when compared with benign prostate epithelium. A luciferase reporter assay demonstrated that miR505 directly targeted NRCAM in PCa cells. In addition, NRCAM stimulation antagonized the inhibitory effects of miR505 on the proliferation, migration, and invasion of PCa cells. Furthermore, lower levels of miR505 and higher levels of NRCAM may serve as a predictor of worse biochemical recurrencefree survival or diseasefree survival in patients with PCa. In conclusion, the present study revealed the inhibitory effects of miR505 on PCa tumorigenesis, which potentially occur by targeting NRCAM. The combined analysis of NRCAM and miR505 may predict disease progression in patients with PCa following radical prostatectomy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Biomarcadores Tumorais
/
Moléculas de Adesão Celular
/
Regulação Neoplásica da Expressão Gênica
/
MicroRNAs
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article